Selected prospective trials of immune checkpoint agents in lymphoma
| Agent . | Phase/trial name . | Clinical setting . | No. of patients . | ORR, % . | CR rate, % . | Median PFS . |
|---|---|---|---|---|---|---|
| cHL | ||||||
| Nivolumab22 | 1/CheckMate 039 | R/R | 23 | 87 | 17 | Not reached |
| Nivolumab25,26 | 2/CheckMate 205 | R/R | 80 | 68 | 9 | 14.8 mo |
| Pembrolizumab23,24 | 1/KEYNOTE-013 | R/R | 31 | 65 | 16 | 11.4 mo |
| Pembrolizumab27,28 | 2/KEYNOTE-087 | R/R | 210 | 69 | 22 | Not reached |
| Nivolumab + ipilimumab31 | 1/CheckMate 039 | R/R | 31 | 74 | 19 | Not reached |
| Nivolumab + brentuximab32 | 1/2 | R/R, initial salvage regimen | 62 | 85 | 63 | Not reached |
| Nivolumab + brentuximab33 | 1 | R/R | 18 | 89 | 50 | Not reached |
| FL | ||||||
| Pidilizumab + rituximab58 | 2 | R/R | 32 | 66 | 52 | 18.8 mo |
| Nivolumab50 | 1 | R/R | 10 | 40 | 10 | Not reached |
| Nivolumab + ipilimumab31 | 1 | R/R | 5 | 20 | 0 | Not reached |
| Atezolizumab + obinatuzumab53 | 2 | R/R | 26 | 57 | Not reported | Not reached |
| Pembrolizumab + rituximab60 | 2 | R/R | 30 | 80 | 60 | Not reached |
| Utomilumab + rituximab61 | 1/2 | R/R | 33 | 27 | 12 | Not reached |
| DLBCL | ||||||
| Pidilizumab + rituximab52 | 2 | Consolidation after ASCT | 66 | 51* | 34 | 72% (at 16 mo) |
| Nivolumab50 | 1 | R/R | 11 | 36 | 18 | 7 wk |
| Nivolumab + ipilimumab31 | 1 | R/R | 10 | 20 | 0 | Not reached |
| Atezolizumab + obinatuzumab53 | 2 | R/R | 23 | 16 | Not reported | Not reached |
| PMBL | ||||||
| Pembrolizumab46 | 1/KEYNOTE-013 | R/R | 18 | 41 | 12 | Not reached |
| RT | ||||||
| Pembrolizumab51 | 1 | R/R | 9 | 44 | 11 | 5.4 mo |
| TCL | ||||||
| Nivolumab50 | 1 | R/R | 13 MF | 15 | 0 | 10 wk |
| 5 PTCL | 40 | 0 | 14 wk | |||
| 5 Other | 0 | 0 | 7-10 wk | |||
| Nivolumab + ipilimumab31 | 1 | R/R | 7 CTCL | 0 | 0 | Not reached |
| 4 PTCL | 25 | 0 | ||||
| Pembrolizumab64 | 2 | R/R | 15 SS | 27 | 7 | 69% (at 1 y) |
| 9 MF | 55 | 0 |
| Agent . | Phase/trial name . | Clinical setting . | No. of patients . | ORR, % . | CR rate, % . | Median PFS . |
|---|---|---|---|---|---|---|
| cHL | ||||||
| Nivolumab22 | 1/CheckMate 039 | R/R | 23 | 87 | 17 | Not reached |
| Nivolumab25,26 | 2/CheckMate 205 | R/R | 80 | 68 | 9 | 14.8 mo |
| Pembrolizumab23,24 | 1/KEYNOTE-013 | R/R | 31 | 65 | 16 | 11.4 mo |
| Pembrolizumab27,28 | 2/KEYNOTE-087 | R/R | 210 | 69 | 22 | Not reached |
| Nivolumab + ipilimumab31 | 1/CheckMate 039 | R/R | 31 | 74 | 19 | Not reached |
| Nivolumab + brentuximab32 | 1/2 | R/R, initial salvage regimen | 62 | 85 | 63 | Not reached |
| Nivolumab + brentuximab33 | 1 | R/R | 18 | 89 | 50 | Not reached |
| FL | ||||||
| Pidilizumab + rituximab58 | 2 | R/R | 32 | 66 | 52 | 18.8 mo |
| Nivolumab50 | 1 | R/R | 10 | 40 | 10 | Not reached |
| Nivolumab + ipilimumab31 | 1 | R/R | 5 | 20 | 0 | Not reached |
| Atezolizumab + obinatuzumab53 | 2 | R/R | 26 | 57 | Not reported | Not reached |
| Pembrolizumab + rituximab60 | 2 | R/R | 30 | 80 | 60 | Not reached |
| Utomilumab + rituximab61 | 1/2 | R/R | 33 | 27 | 12 | Not reached |
| DLBCL | ||||||
| Pidilizumab + rituximab52 | 2 | Consolidation after ASCT | 66 | 51* | 34 | 72% (at 16 mo) |
| Nivolumab50 | 1 | R/R | 11 | 36 | 18 | 7 wk |
| Nivolumab + ipilimumab31 | 1 | R/R | 10 | 20 | 0 | Not reached |
| Atezolizumab + obinatuzumab53 | 2 | R/R | 23 | 16 | Not reported | Not reached |
| PMBL | ||||||
| Pembrolizumab46 | 1/KEYNOTE-013 | R/R | 18 | 41 | 12 | Not reached |
| RT | ||||||
| Pembrolizumab51 | 1 | R/R | 9 | 44 | 11 | 5.4 mo |
| TCL | ||||||
| Nivolumab50 | 1 | R/R | 13 MF | 15 | 0 | 10 wk |
| 5 PTCL | 40 | 0 | 14 wk | |||
| 5 Other | 0 | 0 | 7-10 wk | |||
| Nivolumab + ipilimumab31 | 1 | R/R | 7 CTCL | 0 | 0 | Not reached |
| 4 PTCL | 25 | 0 | ||||
| Pembrolizumab64 | 2 | R/R | 15 SS | 27 | 7 | 69% (at 1 y) |
| 9 MF | 55 | 0 |
CTCL, cutaneous T-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MF, mycosis fungoides; PMBL, primary mediastinal B cell lymphoma; PTCL, peripheral T cell lymphoma; RT, Richter's transformation; SS, Sézary syndrome.
Among the 35 patients with measurable disease following ASCT.